Pyxis Oncology Inc.

1.26
-0.07 (-5.26%)
At close: Feb 11, 2025, 3:59 PM
1.33
5.14%
After-hours Feb 11, 2025, 05:17 PM EST
undefined%
Bid 1.25
Market Cap 75.22M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.06
PE Ratio (ttm) -1.19
Forward PE n/a
Analyst Buy
Ask 1.33
Volume 1,056,936
Avg. Volume (20D) 1,306,398
Open 1.30
Previous Close 1.33
Day's Range 1.23 - 1.36
52-Week Range 1.23 - 6.85
Beta undefined

About PYXS

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2021
Employees 54
Stock Exchange NASDAQ
Ticker Symbol PYXS

Analyst Forecast

According to 6 analyst ratings, the average rating for PYXS stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 690.51% from the latest price.

Buy 83.33%
Hold 16.67%
Sell 0.00%
Stock Forecasts
2 months ago
-45.03%
Pyxis Oncology shares are trading lower after Will... Unlock content with Pro Subscription
2 months ago
-8.17%
Pyxis Oncology shares are trading higher after the company announced PYX-201 clinical Phase 1 part 1 data.